test44
https://www.cytel.com/blog/winter-weekend-read-the-fundamentals-of-real-world-evidence-in-oncology-drug-development
March 18, 2022
Real world evidence (RWE) provides a large and growing source of insights into drug uptake and safety. It is..
Read article
test44
https://www.cytel.com/blog/leveraging-staged-investment-strategy-for-funding-novel-therapies
October 27, 2021
A staged investment strategy aligns R&D decisions and financial planning with the interim looks of a clinical trial. If..
Read article
test44
https://www.cytel.com/blog/strategic-clinical-trial-design-unlocks-innovative-financing-opportunity
October 20, 2021
For health innovators, trial selection is a key success factor as there are no second chances. But how do you find the..
Read article
test44
https://www.cytel.com/blog/what-does-it-mean-to-reduce-the-risk-of-a-faulty-conclusion-a-closer-look-at-a-new-case-study
August 18, 2021
During the design of a clinical trial, many biotechs want to substantially reduce the risk of a good new therapy being..
Read article
test44
https://www.cytel.com/blog/lessons-learned-from-leveraging-computing-power-for-clinical-strategy
July 28, 2021
“We found an optimal design in hours that might have taken months to find using standard methods,” reflected Fabien..
Read article
test44
https://www.cytel.com/blog/the-risk-of-under-exploring-trial-design-options-case-study
July 22, 2021
Earlier this year, Cytel founder Cyrus Mehta observed that clinical trial design is often treated like an art rather..
Read article
test44
https://www.cytel.com/blog/icase-study-trial-design-cdisc-submission
May 17, 2017
This new case study shares how Cytel supported a specialist biopharmaceutical company from Phase 2 trial design through..
Read article
test44
https://www.cytel.com/blog/improving-go-no-go-decision-making-custom-software
March 24, 2017
Robust go/no-go (GNG) decision-making is essential for effectively managing risk across a clinical portfolio. In early..
Read article
test44
https://www.cytel.com/blog/case-study-ulcerative-colitis-modeling
November 18, 2016
Challenge Our client had the following key questions which they wanted our pharmacometrics group to address for an..
Read article